CELT ACD Vascular Closure Device
Vasorum, Ltd. · Decision date Dec 18, 2025
What did the FDA decide?
FDA records P150006/S007 as a supplement to PMA P150006, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 18, 2025.
FDA approval order statement
a new adhesive to be used in the Tyvek packaging lid
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 18, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P150006/S007
- Regulatory pathway
- PMA supplement
- Applicant
- Vasorum, Ltd.
- Product code
- MGB
- Decision code
- OK30
- Decision date
- Dec 18, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Vasorum, Ltd.
- Product code
- MGB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150006. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150006 · Original PMA
CELT ACD VASCULAR CLOSURE DEVICE
P150006/S007 received
Application receipt date recorded by FDA.
P150006/S007 · FDA decision
30-Day Notice
P150006/S009 · Related supplement
CELT ACD VASCULAR CLOSURE DEVICE
Timeline entries are records held by MedtechLedger for P150006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Vasorum, Ltd. | PMA approval | Jul 20, 2016 | FDA | |
CELT ACD VASCULAR CLOSURE DEVICEP150006/S009 | Vasorum, Ltd. | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA | |
| Vivasure Medical , Ltd. | PMA approval | Oct 16, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
VASCADE 5F Vascular Closure SystemP120016/S043 | Cardiva Medical, Inc. | PMA supplement | Sep 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vasorum, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2012 Orchard Ave., Citywest Business Campus, Dublin, 24
Sources and methodology
- Original FDA record: P150006/S007
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



